Skip to main content

Table 2 Cost-effectiveness results, base case analysis

From: Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting

  BAY 81–8973 rAHF-PFM Incremental
Drug/Procedure cost ¥16,329,777 ¥16,325,648 ¥4,129
Bleeding related costs ¥486,877 ¥612,852 -¥125,974
Physician visits ¥108,348 ¥108,321 ¥27
Societal cost ¥5,388 ¥5,390 -¥2
Total cost ¥16,930,390 ¥17,052,210 -¥121,819
 QALYs 13.220 13.167 0.053
 Life years 18.058 18.053 0.005
ICER BAY 81–8973 is dominant (lower costs and higher QALY gain)
  1. ICER Incremental cost-effectiveness ratio, rAHF-PFM: antihemophilic factor (recombinant) plasma/albumin-free method; QALYs: quality-adjusted life year